

Management of chronic hepatitis C in the elderly not eligible for standard treatment



Karin Lindahl

The size of the problem...

EU

- The proportion of senior citizens in Europe's population is rising steadily, and by 2020 a quarter of this population will be over 65 years of age.




Age-related statistics


- Average life expectancy:
- Sweden: 82 yrs
- Rep of Moldova: 69 yrs

Age-related statistics from Sweden, Prognosis

Approx 20% are >65 yrs



Approx 5 % are > 85 yrs



©

To treat or not to treat???



Risks?

Efficacy/tolerance data?

ESCMID Online
© by author

Lecture Library

To consider....



- Risk factors for complications (Cirrosis, HCC)
- Treatment tolerance
- Treatment options

Precautions

- Co-morbidities (anemia, renal function)
- Metabolic syndrome, occult coronary disease
- Less for DAAs? (few included in RCTs...)

Indications

- Biological aging contra chronological aging
- Liver fibrosis
- Extrahepatic manifestations



Standard treatment?

- PegIFN + Rib
- PegIFN + Rib + 1st gen PI
- NUC + PegIFN + Rib, NUC + Rib , NUC + 2nd gen PI +/- Rib, NUC + NS5A inh +/- Rib, other?



Ethics contra economics...

- What is cost benefit?
- For whom? The individual contra the community....
- Do we need more studies or just less expensive drugs?



Local data

- Dep of Infectious Diseases, Karolinska University Hospital
- Hepatitis Referral Centre
- 9000 visits / year (30% to specialized nurses)
- 300-400 treated patients yearly
- “InfCareHepatitis” data base, national register

InfCareHepatitis, Stockholm data


- > 1000 patients more than 60 yrs (30% female)
- 300 treatment naïve
- At least 60 with cirrosis/ >11 kPa
- 740 already treated or ongoing (incl lost to follow up, deceased)

Male born -43

- Referred to us 1997
- Taxi driver, almost no alcohol
- Type II DM
- Mild asthma


- Liver biopsy 1998 : F3
- Gt 1a
- Treated: StIFN+rib+amantadine (clin trial) 24w,
NR

InfCare-Id: 100464



Kön	Ansvarig sjukvårdsenhet	Ansvarig läkare	Ansvarig kurator
Man		Karin Lindahl	
Fibrosastadium (HIV)	Inflammationsgrad (I-IV)	Fibroscan (kPa)	HIV serologi
		21,3	
HAV status	HBV status	HCV status	HCV status
Första pos HBV serologi	Genotyp (HBV)		
Första pos HCV serologi	Genotyp (HCV)	Subtyp (HCV)	
1996-01-01	Genotyp 1	a	
Studie	Start	Slut	

ESCMID Online Lecture Library
© by author



Biopsy : F3

Elasticity 14kPa (F4)

Elasticity 21 kPa...

ESCMID Online Lecture Library
© by author

Male born -41

- Referred to us -05
- Actor, slightly bipolar...
- Single, some alcohol periodically, depressive some times
- Blood transfusion -58, once injecting amf -69
- Small stroke -03 fully recovered
- Gt 2b, susp liverfibrosis/cirrosis (slightly lowered plts), but no biopsy



What to do?


- US April 2014:
- 2 susp HCC
- 2,5 and 1,5 cm in diam.

Currently in treatment week 7, HCV RNA
detectable (<15 IU/mL) in treatment week 4...

Male born -40

- Ref -11
- Retired, prev painter, smoker, drinks 2 bottle of wine per week.
- HT, reduced renal function
- Cryoglob pos Gnititis, GFR 45 ml/min
- Gt 2b

ESCMID Online Lecture Library
© by author



- Obstacles are the basis for progress....



Thank you!

